| Literature DB >> 31906362 |
Hye-Eun Lee1,2, Masayoshi Zaitsu2,3, Eun-A Kim4, Ichiro Kawachi2.
Abstract
Background: We aimed to describe inequalities in site-specific cancer survival across different occupational classes in Korean men.Entities:
Keywords: Korea; occupations; socioeconomic factors; survival
Mesh:
Year: 2020 PMID: 31906362 PMCID: PMC6981645 DOI: 10.3390/ijerph17010303
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Selection of study population.
Characteristics of 134,384 male cancer patients.
| N | % | |
|---|---|---|
| Age of Diagnosis | ||
| <20 | 42 | 0.0 |
| 20–29 | 2,156 | 1.6 |
| 30–39 | 13,590 | 10.1 |
| 40–49 | 31,780 | 23.7 |
| 50–59 | 46,729 | 34.8 |
| 60– | 40,087 | 29.8 |
| Year of diagnosis | ||
| 1995–1999 | 19,804 | 14.7 |
| 2000–2004 | 49,771 | 37.0 |
| 2005–2008 | 64,820 | 48.2 |
| Occupational group | ||
| Group 1 (Professionals and managers) | 28,198 | 21.0 |
| Group 2 (Clerks) | 23,937 | 17.8 |
| Group 3 (Service and sales workers) | 8,152 | 6.1 |
| Group 4 (blue-collar workers) | 74,097 | 55.1 |
| Vital status | ||
| Alive | 70,117 | 52.2 |
| Dead | 64,267 | 47.8 |
| cause of death: cancer | 58,332 | (90.8) |
| cause of death: non-cancer | 3,037 | (4.7) |
| cause of death: undefined | 2,898 | (4.5) |
| Total | 134,384 | 100.0 |
Distribution of cancer sites in the study population.
| Site of Cancer | N | % |
|---|---|---|
| All cancer (C00–C97) | 134,384 | 100.0 |
| Lip, oral cavity and pharynx (C00–C14) | 3142 | 2.3 |
| Esophagus (C15) | 2192 | 1.6 |
| Stomach (C16) | 32,524 | 24.2 |
| Colon, rectosigmoid junction, rectum (C18–C20) | 18,361 | 13.7 |
| Liver and intrahepatic bile ducts (C22) | 23,170 | 17.2 |
| Gallbladder, other and unspecified parts of biliary tract (C23–C24) | 2632 | 2.0 |
| Pancreas (C25) | 3068 | 2.3 |
| Larynx (C32) | 1496 | 1.1 |
| Trachea, bronchus and lung (C33–C34) | 14,423 | 10.7 |
| Mesothelioma (C45) | 92 | 0.1 |
| Breast (C50) | 102 | 0.1 |
| Prostate (C61) | 3403 | 2.5 |
| Testis (C62) | 443 | 0.3 |
| Kidney (C64) | 3746 | 2.8 |
| Bladder (C67) | 3329 | 2.5 |
| Brain and other parts of central nervous system (C70–C72) | 1775 | 1.3 |
| Thyroid gland (C73) | 6059 | 4.5 |
| Hodgkin lymphoma (C81) | 264 | 0.2 |
| Non-Hodgkin lymphoma (C82–C85, C96) | 3706 | 2.8 |
| Multiple myeloma (C90) | 701 | 0.5 |
| Leukemia (C91–C95) | 2748 | 2.0 |
Group 1, Professionals and managers; Group 2, Clerks; Group 3, Service and sales workers; Group 4, Blue-collar workers.
Cancer specific HRs and 95% CIs according to occupational groups using Cox proportional hazard model adjusted for age and year of diagnosis.
| Adjusted HR | 95% CI | ||
|---|---|---|---|
| All cancer (C00–C97) | Group 1 | Reference | |
| Group 2 | 1.05 | 1.02–1.08 | |
| Group 3 | 1.38 | 1.33–1.43 | |
| Group 4 | 1.45 | 1.42–1.48 | |
| Lip, oral cavity | Group 1 | Reference | |
| Group 2 | 1.20 | 0.97–1.49 | |
| Group 3 | 1.89 | 1.47–2.42 | |
| Group 4 | 1.78 | 1.51–2.10 | |
| Esophagus (C15) | Group 1 | Reference | |
| Group 2 | 1.14 | 0.91–1.41 | |
| Group 3 | 1.24 | 0.94–1.61 | |
| Group 4 | 1.29 | 1.11–1.51 | |
| Stomach (C16) | Group 1 | Reference | |
| Group 2 | 1.01 | 0.95–1.09 | |
| Group 3 | 1.35 | 1.23–1.47 | |
| Group 4 | 1.31 | 1.24–1.38 | |
| Colon, rectosigmoid junction, rectum (C18–C20) | Group 1 | Reference | |
| Group 2 | 1.15 | 1.05–1.27 | |
| Group 3 | 1.39 | 1.22–1.57 | |
| Group 4 | 1.37 | 1.27–1.47 | |
| Liver and intrahepatic bile ducts (C22) | Group 1 | Reference | |
| Group 2 | 1.06 | 1.01–1.12 | |
| Group 3 | 1.36 | 1.26–1.46 | |
| Group 4 | 1.44 | 1.38–1.50 | |
| Gallbladder, other and unspecified parts of biliary tract (C23–C24) | Group 1 | Reference | |
| Group 2 | 1.14 | 0.96–1.36 | |
| Group 3 | 1.18 | 0.93–1.47 | |
| Group 4 | 1.26 | 1.11–1.44 | |
| Pancreas (C25) | Group 1 | Reference | |
| Group 2 | 1.04 | 0.91–1.19 | |
| Group 3 | 1.23 | 1.03–1.46 | |
| Group 4 | 1.18 | 1.06–1.30 | |
| Larynx (C32) | Group 1 | Reference | |
| Group 2 | 0.94 | 0.57–1.55 | |
| Group 3 | 1.66 | 0.96–2.78 | |
| Group 4 | 1.84 | 1.33–2.60 | |
| Trachea, bronchus and lung (C33–C34) | Group 1 | Reference | |
| Group 2 | 1.10 | 1.02–1.19 | |
| Group 3 | 1.21 | 1.10–1.33 | |
| Group 4 | 1.26 | 1.19–1.33 | |
| Prostate (C61) | Group 1 | Reference | |
| Group 2 | 1.25 | 0.89–1.74 | |
| Group 3 | 2.26 | 1.39–3.52 | |
| Group 4 | 2.35 | 1.85–3.02 | |
| Kidney (C64) | Group 1 | Reference | |
| Group 2 | 0.98 | 0.77–1.24 | |
| Group 3 | 1.19 | 0.84–1.65 | |
| Group 4 | 1.53 | 1.28–1.85 | |
| Bladder (C67) | Group 1 | Reference | |
| Group 2 | 1.04 | 0.76–1.42 | |
| Group 3 | 1.18 | 0.75–1.81 | |
| Group 4 | 1.26 | 1.01–1.60 | |
| Brain and other parts of central nervous system (C70–C72) | Group 1 | Reference | |
| Group 2 | 1.04 | 0.85–1.27 | |
| Group 3 | 1.11 | 0.84–1.45 | |
| Group 4 | 1.22 | 1.04–1.45 | |
| Thyroid gland (C73) | Group 1 | Reference | |
| Group 2 | 1.07 | 0.63–1.79 | |
| Group 3 | 2.59 | 1.25–4.98 | |
| Group 4 | 1.43 | 0.94–2.20 | |
| Non-Hodgkin lymphoma (C82–C85,C96) | Group 1 | Reference | |
| Group 2 | 1.08 | 0.90–1.29 | |
| Group 3 | 1.46 | 1.15–1.84 | |
| Group 4 | 1.46 | 1.27–1.68 | |
| Leukemia (C91–C95) | Group 1 | Reference | |
| Group 2 | 1.04 | 0.89–1.23 | |
| Group 3 | 1.03 | 0.82–1.27 | |
| Group 4 | 1.32 | 1.16–1.50 |
Figure 2Survival curve by occupational group and cancer site. Group 1, Professionals and managers; Group 2, Clerks; Group 3, Service and sales workers; Group 4, Blue-collar workers.